Anakinra in experimental acute myocardial infarction--does dosage or duration of treatment matter?
- PMID: 19005744
- DOI: 10.1007/s10557-008-6154-3
Anakinra in experimental acute myocardial infarction--does dosage or duration of treatment matter?
Abstract
Purpose: Interleukin-1 (IL-1) receptor antagonist (Ra) is a naturally occurring IL-1 blocker with a cardioprotective effect during acute myocardial infarction (AMI). Anakinra, recombinant-human IL-1Ra, has been used to prevent heart failure in a mouse model of AMI. The aim of this study was to determine the optimal therapeutic regimen for anakinra in AMI.
Methods: We performed dose-response experiments comparing anakinra 1 mg/kg with 100 mg/kg doses, and duration-response experiments comparing 1-week to 2-week treatment. Echocardiography was used to assess cardiac remodeling and systolic function. Histopathology was used to detect apoptotic cardiomyocytes.
Results: A higher dose of anakinra was not associated with additional improvement in cardiac remodeling or function. The 2-week anakinra treatment had sustained and more favorable remodeling and systolic function compared to 1-week treatment with significantly smaller left ventricular end-systolic diameter and greater fractional shortening 4 weeks after AMI.
Conclusion: Anakinra inhibits apoptosis and ameliorates cardiac remodeling up to 4 weeks after infarction. A 2-week regimen is superior to a 1-week regimen, whereas a higher dose did not provide any further benefit over standard doses.
Similar articles
-
Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction.Circulation. 2008 May 20;117(20):2670-83. doi: 10.1161/CIRCULATIONAHA.107.740233. Epub 2008 May 12. Circulation. 2008. PMID: 18474815
-
Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study).Am J Cardiol. 2010 May 15;105(10):1371-1377.e1. doi: 10.1016/j.amjcard.2009.12.059. Epub 2010 Apr 2. Am J Cardiol. 2010. PMID: 20451681 Clinical Trial.
-
Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice.J Cardiovasc Pharmacol. 2010 Feb;55(2):117-22. doi: 10.1097/FJC.0b013e3181c87e53. J Cardiovasc Pharmacol. 2010. PMID: 19920765
-
High dose aspirin and left ventricular remodeling after myocardial infarction: aspirin and myocardial infarction.Basic Res Cardiol. 2007 Jul;102(4):334-40. doi: 10.1007/s00395-007-0647-2. Epub 2007 Mar 8. Basic Res Cardiol. 2007. PMID: 17340057
-
New Therapies to Modulate Post-Infarction Inflammatory Alterations in the Myocardium: State of the Art and Forthcoming Applications.Curr Radiopharm. 2021;14(3):273-299. doi: 10.2174/1874471013666201210140743. Curr Radiopharm. 2021. PMID: 33302861 Review.
Cited by
-
Role of Interleukin-1 in Radiation-Induced Cardiomyopathy.Mol Med. 2015 Mar 26;21(1):210-8. doi: 10.2119/molmed.2014.00243. Mol Med. 2015. PMID: 25822795 Free PMC article.
-
Cytoprotective activated protein C averts Nlrp3 inflammasome-induced ischemia-reperfusion injury via mTORC1 inhibition.Blood. 2017 Dec 14;130(24):2664-2677. doi: 10.1182/blood-2017-05-782102. Epub 2017 Sep 7. Blood. 2017. PMID: 28882883 Free PMC article.
-
Methylation of Apoptosis-Associated Speck-Like Protein With a Caspase Recruitment Domain and Outcomes in Heart Failure.J Card Fail. 2016 May;22(5):340-6. doi: 10.1016/j.cardfail.2015.12.004. Epub 2015 Dec 14. J Card Fail. 2016. PMID: 26700661 Free PMC article.
-
NLRP3 Inflammasome Inhibitors in Cardiovascular Diseases.Molecules. 2021 Feb 12;26(4):976. doi: 10.3390/molecules26040976. Molecules. 2021. PMID: 33673188 Free PMC article. Review.
-
Targeting interleukin-1 in heart disease.Circulation. 2013 Oct 22;128(17):1910-23. doi: 10.1161/CIRCULATIONAHA.113.003199. Circulation. 2013. PMID: 24146121 Free PMC article. Review. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
